Skip to main content
Clinical Trials/NCT01302574
NCT01302574
Completed
Phase 1

The Role of Sweet Taste Receptor Blockade on Intragastric Liquid Meal-stimulated Secretion of Satiation Peptides in Healthy Humans

University Hospital, Basel, Switzerland1 site in 1 country16 target enrollmentJanuary 2010

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Taste Disorder, Secondary, Sweet
Sponsor
University Hospital, Basel, Switzerland
Enrollment
16
Locations
1
Primary Endpoint
Gastrointestinal peptide secretion
Status
Completed
Last Updated
15 years ago

Overview

Brief Summary

The purpose of this study is to determine the functional significance of sweet taste receptors in the secretion of gastrointestinal (GI) satiation peptides by using a specific sweet taste receptor antagonist to block sweet taste perception in the gastrointestinal tract.

Detailed Description

There is strong evidence that taste signaling mechanisms identified in the oral epithelium also operate in the gut. It is suggested that open-type enteroendocrine cells directly sense nutrient via alpha-gustducin coupled taste receptors to modulate the secretion of glucagon like peptide-1 (GLP-1) and peptide YY (PYY). Several nutrient responsive G-protein coupled receptors have been identified in the human gut, including the sweet taste responsive T1R2/T1R3 heterodimer, the amino acid/umami responsive T1R1/T1R3 as well as GPR120 for unsaturated long-chain free fatty acids. The functional significance of sweet taste receptors in mixed liquid meal-stimulated secretion of GLP-1 and PYY will be determined by intragastric infusion of a 500 mL mixed liquid meal with or without lactisole (450 ppm)in a double blind, 2-way crossover trial including 16 healthy subjects.

Registry
clinicaltrials.gov
Start Date
January 2010
End Date
June 2010
Last Updated
15 years ago
Study Type
Interventional
Study Design
Crossover
Sex
All

Investigators

Sponsor
University Hospital, Basel, Switzerland

Eligibility Criteria

Inclusion Criteria

  • healthy subjects
  • BMI of 19.0-24.5
  • age 18-40 years old
  • stable body weight for at least 3 month

Exclusion Criteria

  • substance abuse
  • regular intake of medication
  • medical or psychiatric illness
  • gastrointestinal disorders or food allergies

Outcomes

Primary Outcomes

Gastrointestinal peptide secretion

Time Frame: 2 hours blood sampling

Secondary Outcomes

  • Appetite perceptions(4 hours)
  • Gastric emptying rate(4 hours)

Study Sites (1)

Loading locations...

Similar Trials